As a result, many novel biologics targeting pivotal markers in the type 2 inflammation pathway, such as IgE, IL-5, and IL-4Rα, originally developed for uncontrolled asthma, are recommended for treating refractory or uncontrolled CRSwNP.15 Here, IL5 is linked to chronic rhinosinusitis with nasal polyps.